The fine points of end points: phase II trials in lung cancer.
Gelmon
K A
KA
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents